GNAS and KRAS Mutations are Common in Intraductal Papillary Neoplasms of the Bile Duct

Intraductal papillary neoplasms of the bile duct (IPNB) shows favorable prognosis and is regarded as a biliary counterpart of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Although activating point mutations of GNAS at codon 201 have been detected in approximately two thirds of IPMNs of the pancreas, there have been few studies on GNAS mutations in IPNBs. This study investigates the status of GNAS and KRAS mutations and their association with clinicopathological factors in IPNBs. We examined the status of GNAS mutation at codon 201 and KRAS mutation at codon 12&13, degree of mucin production and immunohistochemical expressions of MUC mucin core proteins in 29 patients (M/F = 15/14) with IPNB in intrahepatic and perihilar bile ducts (perihilar IPNB) and 6 patients (M/F = 5/1) with IPNB in distal bile ducts (distal IPNB). GNAS mutations and KRAS mutations were detected in 50% and 46.2% of IPNBs, respectively. There was no significant correlation between the status of GNAS mutation and clinicopathological factors in IPNBs, whereas, the status of KRAS mutation was significantly inversely correlated with the degree of MUC2 expression in IPNBs (p<0.05). All IPNBs with GNAS mutation only showed high-mucin production. Degree of mucin production was significantly higher in perihilar IPNBs than distal IPNBs (p<0.05). MUC2 and MUC5AC expression was significantly higher in IPNBs with high-mucin production than those with low-mucin production (p<0.01 and p<0.05, respectively). In conclusions, this study firstly disclosed frequent GNAS mutations in IPNBs, similarly to IPMNs. This may suggest a common histopathogenesis of IPNBs and IPMNs. The status of KRAS mutations was inversely correlated to MUC2 expression and this may suggest heterogeneous properties of IPNBs. IPNBs with high-mucin production are characterized by perihilar location and high expression of MUC2 and MUC5AC, irrespective of the status of GNAS and KRAS mutations.

[1]  Maylee Hsu,et al.  KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas , 2013, Cancer.

[2]  H. Tsuda,et al.  Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum , 2013, The Journal of pathology.

[3]  T. Mori,et al.  Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms , 2013, British Journal of Cancer.

[4]  K. Tsuneyama,et al.  Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct , 2013, Histopathology.

[5]  K. Kinzler,et al.  GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  M. D'Angelica,et al.  Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? , 2012, Hepatology.

[7]  N. Rigby,et al.  Lamellar structures of MUC2-rich mucin: a potential role in governing the barrier and lubricating functions of intestinal mucus. , 2012, Biomacromolecules.

[8]  H. Tsuda,et al.  Frequent activating GNAS mutations in villous adenoma of the colorectum , 2012, The Journal of pathology.

[9]  Bin Tean Teh,et al.  Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.

[10]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[11]  Masakazu Yamamoto,et al.  Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas , 2011, Scientific reports.

[12]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[13]  M. Miyazaki,et al.  Similarities and Differences Between Intraductal Papillary Tumors of the Bile Duct With and Without Macroscopically Visible Mucin Secretion , 2011, The American journal of surgical pathology.

[14]  Y. Nakanuma.  A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: Is the biliary tract an incomplete pancreas? , 2010, Pathology international.

[15]  Y. Nakanuma,et al.  Over‐expression of polycomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis , 2008, The Journal of pathology.

[16]  Y. Nakanuma,et al.  Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. , 2007, Progress in histochemistry and cytochemistry.

[17]  W. Chung,et al.  Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission , 2007, Pituitary.

[18]  M. Miles,et al.  The isolated MUC5AC gene product from human ocular mucin displays intramolecular conformational heterogeneity. , 2007, Glycobiology.

[19]  Y. Jan,et al.  Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis , 2004, Laboratory Investigation.

[20]  S. Batra,et al.  Pathologic Features of Mucin-producing Bile Duct Tumors: Two Histopathologic Categories as Counterparts of Pancreatic Intraductal Papillary-mucinous Neoplasms , 2004, The American journal of surgical pathology.

[21]  E. Furth,et al.  Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. , 2003, Human pathology.

[22]  S. Myung,et al.  Mucin-Hypersecreting Bile Duct Tumor Characterized by a Striking Homology with an Intraductal Papillary Mucinous Tumor (IPMT) of the Pancreas , 2000, Endoscopy.

[23]  Y. Kim,et al.  Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: An immunohistochemical study , 1996, Hepatology.

[24]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[25]  Y. Nakanuma,et al.  Expression of blood group‐related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases , 1989, Hepatology.

[26]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[27]  J. Tran van Nhieu,et al.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. , 2012, Journal of hepatology.

[28]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[29]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.